Neuroprotection by Orexin-A via HIF-1α induction in a cellular model of Parkinson's disease

Neuroscience Letters

Volumn 579, Issue , 2014, Pages 35-40

  Feng, Ya ^a   Liu, Te ^b   Li, Xin Qun ^c   Liu, Ye ^a   Zhu, Xiao Ying ^a   Jankovic, Joseph ^d   Pan, Tian Hong ^d   Wu, Yun Cheng ^a  

^a SHANGHAI FIRST PEOPLE S HOSPITAL   (China)

^b LONGHUA HOSPITAL AFFILIATED TO SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Dopaminergic neuron; HIF 1 ; Neurodegenerative disease; Neuroprotection; Orexin A; Parkinson's disease

Indexed keywords

ERYTHROPOIETIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; OREXIN A; VASCULOTROPIN; NEUROPEPTIDE; NEUROPROTECTIVE AGENT; OREXINS; SIGNAL PEPTIDE; VASCULOTROPIN A;

ARTICLE; CELL DAMAGE; CELL VIABILITY; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IN VITRO STUDY; NEUROPROTECTION; NUCLEOTIDE SEQUENCE; PARKINSON DISEASE; PRIORITY JOURNAL; BIOSYNTHESIS; CELL LINE; CHEMICALLY INDUCED; DRUG EFFECTS; GENE REPRESSION; HUMAN; INTOXICATION; METABOLISM; PATHOLOGY;

CELL LINE; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MPTP POISONING; NEUROPEPTIDES; NEUROPROTECTIVE AGENTS; SUPPRESSION, GENETIC; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84904889193     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2014.07.014     Document Type: Article

References (32)

1. Ahn E.H., Kim D.W., Shin M.J., Kim H.R., Kim S.M., Woo S.J., Eom S.A., Jo H.S., Kim D.S., Cho S.W., Park J., Eum W.S., Choi S.Y. PEP-1-PEA-15 protects against toxin-induced neuronal damage in a mouse model of Parkinson's disease. Biochim. Biophys. Acta 2014, 1840:1686-1700.
2. Bader H.L., Hsu T. Systemic VHL gene functions and the VHL disease. FEBS Lett. 2012, 586:1562-1569.
3. Bieganska K., Sokolowska P., Johren O., Zawilska J.B. Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism. J. Mol. Neurosci. 2012, 48:706-712.
4. Butterick T.A., Billington C.J., Kotz C.M., Nixon J.P. Orexin pathways to obesity resistance?. Rev. Endocr. Metab. Disord. 2013, 14:357-364.
5. Butterick T.A., Nixon J.P., Billington C.J., Kotz C.M. Orexin A decreases lipid peroxidation and apoptosis in a novel hypothalamic cell model. Neurosci. Lett. 2012, 524:30-34.
6. Chen H., Guan Y., Yuan G., Zhang Q., Jing N. A perylene derivative regulates HIF-1α and Stat3 signaling pathways. Bioorg. Med. Chem. 2013, 22:1496-1505.
7. Correia S.C., Moreira P.I. Hypoxia-inducible factor 1: a new hope to counteract neurodegeneration?. J. Neurochem. 2010, 112:1-12.
8. Crabtree D., Dodson M., Ouyang X., Boyer-Guittaut M., Liang Q., Ballestas M.E., Fineberg N., Zhang J. Over-expression of an inactive mutant cathepsin D increases endogenous alpha-synuclein and cathepsin B activity in SH-SY5Y cells. J. Neurochem. 2014, 128:950-961.
9. +-induced neuronal apoptosis. Neurochem. Int. 2011, 59:945-953.
10. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
11. Fronczek R., van Geest S., Frölich M., Overeem S., Roelandse F.W., Lammers G.J., Swaab D.F. Hypocretin (orexin) loss in Alzheimer's disease. Neurobiol. Aging 2012, 33:1642-1650.
12. Galanis A., Pappa A., Giannakakis A., Lanitis E., Dangaj D., Sandaltzopoulos R. Reactive oxygen species and HIF-1 signalling in cancer. Cancer Lett. 2008, 266:12-20.
13. Hoyer D., Jacobson L.H. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand?. Neuropeptides 2013, 47:477-488.
14. Inutsuka A., Yamanaka A. The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin/hypocretin. Nagoya J. Med. Sci. 2013, 75:29-36.
15. Kaelin W.G., Ratcliffe P.J. Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway. Mol. Cell 2008, 30:393-402.
16. Langston J.W., Ballard P., Tetrud J.W., Irwin I. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science 1983, 219:979-980.
17. Lee D.W., Rajagopalan S., Siddiq A., Gwiazda R., Yang L., Beal M.F., Ratan R.R., Andersen J.K. Inhibition of prolyl hydroxylase protects against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity: model for the potential involvement of the hypoxia-inducible factor pathway in Parkinson disease. J. Biol. Chem. 2009, 284:29065-29076.
18. Mediavilla C., Risco S. Orexin: clinical and therapeutic implications. Rev. Neurol. 2014, 58:117-124.
19. Reischl S., Li L., Walkinshaw G., Flippin L.A., Marti H.H., Kunze R. Inhibition of HIF prolyl-4-hydroxylases by FG-4497 reduces brain tissue injury and edema formation during ischemic stroke. PLOS ONE 2014, 9:e84767.
20. Schmidt F.M., Kratzsch J., Gertz H.-J., Tittmann M., Jahn I., Pietsch U.-C., Kaisers U.X., Thiery J., Hegerl U., Schönknecht P. Cerebrospinal fluid melanin-concentrating hormone (MCH) and hypocretin-1 (HCRT-1, orexin-A) in Alzheimer's disease. PLOS ONE 2013, 8:e63136.
21. Siddiq A., Ayoub I.A., Chavez J.C., Aminova L., Shah S., LaManna J.C., Patton S.M., Connor J.R., Cherny R.A., Volitakis I., Bush A.I., Langsetmo I., Seeley T., Gunzler V., Ratan R.R. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J. Biol. Chem. 2005, 280:41732-41743.
22. Sikder D., Kodadek T. The neurohormone orexin stimulates hypoxia-inducible factor-1 activity. Genes Dev. 2007, 21:2995-3005.
23. Sokołowska P., Urbańska A., Biegańska K., Wagner W., Ciszewski W., Namiecińska M., Zawilska J.B. Orexins protect neuronal cell cultures against hypoxic stress: an involvement of Akt signaling. J. Mol. Neurosci. 2014, 52:48-55.
24. 2 tension. Proc. Natl. Acad. Sci. U.S.A. 1995, 92:5510-5514.
25. Wang Y., Kilic E., Kilic Ü., Weber B., Bassetti C.L., Marti H.H., Hermann D.M. VEGF overexpression induces post-ischaemic neuroprotection, but facilitates haemodynamic steal phenomena. Brain 2005, 128:52-63.
26. Wienecke M., Werth E., Poryazova R., Baumann-Vogel H., Bassetti C.L., Weller M., Waldvogel D., Storch A., Baumann C.R. Progressive dopamine and hypocretin deficiencies in Parkinson's disease: is there an impact on sleep and wakefulness?. J. Sleep Res. 2012, 21:710-717.
27. Wu Y., Li X., Xie W., Jankovic J., Le W., Pan T. Neuroprotection of deferoxamine on rotenone-induced injury via accumulation of HIF-1α and induction of autophagy in SH-SY5Y cells. Neurochem. Int. 2010, 57:198-205.
28. Xiong X., White R.E., Xu L., Yang L., Sun X., Zou B., Pascual C., Sakurai T., Giffard R.G., Xie X.S. Mitigation of murine focal cerebral ischemia by the hypocretin/orexin system is associated with reduced inflammation. Stroke 2013, 44:764-770.
29. Xue Y.Q., Ma B.F., Zhao L.R., Tatom J.B., Li B., Jiang L.X., Klein R.L., Duan W.M. AAV9-mediated erythropoietin gene delivery into the brain protects nigral dopaminergic neurons in a rat model of Parkinson's disease. Gene Ther. 2010, 17:83-94.
30. Yu Z., Zhao X., Ge Y., Zhang T., Huang L., Zhou X., Xie L., Liu J., Huang G. A regulatory feedback loop between HIF-1α and PIM2 in HepG2 cells. PLOS ONE 2014, 9:e88301.
31. Yuan L.-B., Dong H.-L., Zhang H.-P., Zhao R.-N., Gong G., Chen X.-M., Zhang L.-N., Xiong L. Neuroprotective effect of orexin-A is mediated by an increase of hypoxia-inducible factor-1 activity in rat. Anesthesiology 2011, 114:340-354.
32. Zadori D., Szalardy L., Toldi J., Fulop F., Klivenyi P., Vecsei L. Some molecular mechanisms of dopaminergic and glutamatergic dysfunctioning in Parkinson's disease. J. Neural Transm. 2013, 120:673-681.